Komatsuda A, Wakui H, Ohtani H, Kodama T, Miki K, Imai H, Miura A B
Third Department of Internal Medicine, Akita University School of Medicine, and the Department of Internal Medicine, Yamamoto General Hospital, Akita, Japan.
Am J Kidney Dis. 2000 Mar;35(3):E9. doi: 10.1016/s0272-6386(00)70221-6.
A 64-year-old man developed multiple myeloma (kappa light chain type), nephrotic syndrome, and renal insufficiency in 1993. A renal biopsy showed typical histological findings of light chain nephropathy: nodular glomerulosclerosis with deposition of kappa light chains in the mesangial area and subendothelial space of the glomerular capillary walls. Long-term intermittent MEVP chemotherapy (melphalan, 4 mg/d for 4 days; cyclophosphamide, 100 mg/d for 4 days; vincristine, 1 mg/d; prednisolone, 40 mg/d for 4 days) diminished proteinuria and improved renal function. In April 1999, a follow-up biopsy showed remarkable diminution of nodular lesions and disappearance of kappa light chain deposits. Although the prognosis of light chain nephropathy has been considered poor, long-term successful chemotherapy can clear light chain deposits and restore renal function.